Spiroxatrine

Spiroxatrine (R 5188) is a selective, dual antagonist of 5-HT1α and α2-adrenergic, with the Ki values of 3.94, 224000, 118.5 nM for 5-HT1α, 5-HT1β and 5-HT2, respectively. Spiroxatrine (R 5188) has a sedative effect[1][2][3][4].

Product Specifications

CAS Number

[1054-88-2]

Product Name Alternative

R 5188

UNSPSC

12352005

Target

5-HT Receptor; Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/spiroxatrine.html

Purity

99.25

Solubility

DMSO : 1.92 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NCN(C2=CC=CC=C2)C13CCN(CC4OC5=CC=CC=C5OC4)CC3

Molecular Formula

C22H25N3O3

Molecular Weight

379.45

References & Citations

[1]D L Nelson, et al. Spiroxatrine: a selective serotonin1A receptor antagonist. Eur J Pharmacol. 1986 May 13;124 (1-2) :207-8.|[2]Linda Cleary, et al. Investigation of neurotransmission in vas deferens from alpha (2A/D) -adrenoceptor knockout mice. Br J Pharmacol. 2002 Jul;136 (6) :857-64.|[3]Z-Y Liu, et al. Involvement of 5-hydroxytryptamine (1A) receptors in the descending anti-nociceptive pathway from periaqueductal gray to the spinal dorsal horn in intact rats, rats with nerve injury and rats with inflammation. Neuroscience. 2002;112 (2) :399-407.|[4]W J McBride, et al. Spiroxatrine augments fluoxetine-induced reduction of ethanol intake by the P line of rats. Pharmacol Biochem Behav. 1989 Oct;34 (2) :381-6.